Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Darovasertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma

    31 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-302415020.html

    PR NEWSWIRE
    31 Mar 2025
    Share Share
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-business-update-302214993.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO

    05 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169554&sid=2

    PHARMABIZ
    05 Jun 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asco-and-clinical-update-for-phase-2-company-sponsored-neoadjuvant-study-302161137.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation

    23 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-abstract-summary-results-of-asco-2024-oral-presentation-for-phase-2-investigator-sponsored-study-of-darovasertib-in-neoadjuvant-uveal-melanoma-302154551.html

    PR NEWSWIRE
    23 May 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session

    24 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study-302125242.html

    PR NEWSWIRE
    24 Apr 2024
    Share Share